PAX5 and leukemia: The immunocytochemistry for PAX5 suggests that at least at the moment of the clinical remission, there was no expression of a transcription factor of lymphoid origin, and between the first and second leukemias, there was a period of time where there were no data supporting lymphoid malignancy until the patient relapsed.